Akero Therapeutics Inc (AKRO)
31.20
+0.56
(+1.84%)
USD |
NASDAQ |
Nov 21, 16:00
31.22
+0.02
(+0.06%)
After-Hours: 20:00
Akero Therapeutics Net Income (Quarterly): -72.70M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -72.70M |
June 30, 2024 | -55.99M |
March 31, 2024 | -53.34M |
December 31, 2023 | -55.19M |
September 30, 2023 | -39.66M |
June 30, 2023 | -31.08M |
March 31, 2023 | -25.83M |
December 31, 2022 | -23.06M |
September 30, 2022 | -35.54M |
June 30, 2022 | -27.40M |
March 31, 2022 | -26.03M |
December 31, 2021 | -32.42M |
September 30, 2021 | -24.33M |
June 30, 2021 | -28.93M |
Date | Value |
---|---|
March 31, 2021 | -15.09M |
December 31, 2020 | -29.71M |
September 30, 2020 | -21.40M |
June 30, 2020 | -16.21M |
March 31, 2020 | -11.89M |
December 31, 2019 | -15.61M |
September 30, 2019 | -15.55M |
June 30, 2019 | -7.228M |
March 31, 2019 | -5.362M |
December 31, 2018 | -61.47M |
September 30, 2018 | -11.15M |
June 30, 2018 | -8.673M |
March 31, 2018 | -0.421M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-72.70M
Minimum
Sep 2024
-11.89M
Maximum
Mar 2020
-32.07M
Average
-28.17M
Median
Net Income (Quarterly) Benchmarks
Madrigal Pharmaceuticals Inc | -106.96M |
89bio Inc | -149.07M |
NovaBay Pharmaceuticals Inc | -1.212M |
Palatin Technologies Inc | -7.824M |
iBio Inc | -3.989M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 81.70M |
EPS Diluted (Quarterly) | -1.05 |
Enterprise Value | 1.496B |
Earnings Yield | -12.12% |